权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of iPSC-derived iNKT cells to promote hematopoietic engraftment

开发 iPSC 衍生的 iNKT 细胞以促进造血植入

基本信息

批准号：
10632065
负责人：
Jenny E. Gumperz
金额：
$ 19.44万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10632065
关键词：
Ablation Adjuvant Adult Affect Allogenic Antigen Presentation B-Lymphocytes Bone Marrow Cell Transplantation Bone Marrow Transplantation CD1d antigen CD34 gene Cell Line Cell Therapy Cell physiology Cells Cellular immunotherapy Clinical Cytotoxic T-Lymphocytes Development Dinoprostone Disease E4BP4 Engineering Engraftment Foundations Gene Expression Profiling Genetic Diseases Genetic Transcription Graft vs Tumor Effect Granulocyte-Macrophage Colony-Stimulating Factor HIV Hematological Disease Hematopoietic Hematopoietic Stem Cell Transplantation Human Human Herpesvirus 4 IL17 gene IL3 Gene Immune Immune System Diseases Immunodeficient Mouse Infection Inflammation Inflammatory Interferon Type II Interleukin-10 Interleukin-13 Interleukin-4 Knock-in Knock-out Left Lymphoma Lymphomagenesis Malignant Neoplasms Mediating Modeling Mononuclear Morbidity - disease rate Mus Output Pathologic Patients Predisposition Procedures Production Property Protocols documentation Publishing Signal Transduction System T-Lymphocyte Testing Therapeutic Toxic effect Transplantation Transplantation Conditioning Tumor Burden Umbilical Cord Blood Umbilical Cord Blood Transplantation ZNF145 gene combat conditioning curative treatments cytokine design differential expression factor A graft failure hematopoietic engraftment hematopoietic transplantation high risk improved improved outcome induced pluripotent stem cell induced pluripotent stem cell technology infectious disease treatment insight leukemia relapse monocyte mortality mouse model novel novel therapeutic intervention novel therapeutics overexpression programs response segregation success therapy design transcription factor

项目摘要

Summary Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for a variety of malignancies and other hematological disorders, and also holds promise for treatment of infectious diseases such as HIV. However, HSCT is limited by high risks of morbidity and mortality from complications such as graft failure (which leads to high susceptibility to lethal infections) and leukemic relapse. New strategies to improve outcomes of hematopoietic transplantation would thus have a significant clinical impact. This project focuses on developing invariant Natural Killer T (iNKT) cells derived from human induced pluripotent stem cells (iPSCs) as an adjunct HSCT cellular therapy designed to promote successful hematopoietic engraftment. In recently published preliminary studies, we showed that addition of allogeneic human CD4+ iNKT cells to human umbilical cord blood transplants led to dramatically improved hematopoietic engraftment in immunodeficient mice. The engraftment-promoting activity of iNKT cells was due to their interactions with cord blood monocytes that resulted in production of several potently pro-hematopoietic factors, including the cytokines GM-CSF and IL-3 (produced by iNKT cells), and PGE2 (produced by monocytes in response to signals from iNKT cells). Prior studies in murine models have established that cytokine programs and functional properties of iNKT cells are controlled by two key transcription factors, PLZF and E4BP4. How these transcription factors influence the cytokine profiles of human iNKT cells remains unclear, and specifically, their impact on iNKT cell production of GM-CSF and IL-3 and interactions with monocytes is not known. Aim 1 of this project proposes to generate human iPSC-derived iNKT cells lacking or over-expressing PLZF or E4BP4. Aim 2 will determine the impact of these transcription factors on the ability of iPSC-derived iNKT cells to promote human hematopoietic engraftment and on graft-versus-lymphoma (GVL) activity. Through these studies we will gain highly novel insight into the impact of PLZF and E4BP4 expression on iNKT functional properties, and we will establish the feasibility of generating iPSC-derived iNKT cells with modified transcription factor expression designed to stabilize specific functional programs. This will lay a foundation for designing iPSC-derived iNKT cells that are transcriptionally tuned to promote hematopoietic engraftment without adversely affecting GVL.

总结